Genesis Bioventures, Inc. Announced Today that the Company is Participating in the 2007 International Capital and China Industrial Development Forum in Beijing, China

Genesis Bioventures, Inc. Announced Today that the Company is Participating in the 2007 International Capital and China Industrial Development Forum in Beijing, China

April 26, 2007

    LOS ANGELES, April 26 /Xinhua-PRNewswire/ -- Mr.
Douglas C. Lane, CEO, stated today that Genesis
Bioventures, Inc. were invited to participate in the 2007
International Capital and China Industrial Development
Forum in Beijing. The Company's agent for the Mad Cow
testing in the Pacific Rim, Mr. Stuart Brame with
BioBusiness Development Company, and Dr. Robert Petersen,
President of Prion Developmental Laboratories
("PDL") are attending that conference in Beijing
now. "There is very high interest for PDL's BSE Rapid
Assay product in China. We are very excited to be invited
to participate in this event to promote our Mad Cow disease
testing." Lane said. "We are very excited as well
about the business opportunities in this rapidly expanding
market and see a solid opportunity for PDL's BSE Rapid
Assay to address food safety concerns in China. Mr. Stuart
Brame and BioBusiness Development have been very active
opening new opportunities for us in the Pacific Rim."


    About Genesis Bioventures, Inc. 

Genesis Bioventures, Inc. ("GBI") (OTC Bulletin
Board: GBIW) is a publicly traded biomedical company that
is commercializing two novel diagnostic products that meet
very large global unmet needs: the Mammastatin Serum Assay
("MSA"), a breast cancer diagnostic risk
assessment test, and the Rapid BSE Assay, a fast and cost
effective diagnostic test for on-site detection of Mad Cow
Disease (Bovine Spongiform Encephalopathy "BSE").
The Mammastatin Serum Assay is offered through Biomedical
Diagnostics, LLC, a Genesis Bioventures' wholly owned
subsidiary. The Rapid BSE Assay is offered through Prion
Developmental Laboratories ("PDL"), a Genesis
Bioventures subsidiary investment company. Both products
are at the commercial stage of development. Technology and
product development are completed. Commercial launch will
occur upon closing of the Company's financing. GBI offers
senior executive management, corporate and business
development, financial management, PR, and investment
financing management to both operating companies.

    About the International Capital and China Industrial
Development Forum: 

    In order to strengthen exchange and cooperation between
international capital and Chinese government and its
enterprises, explore channels and modes of supporting the
innovation and development of industrial economies with
international companies, provide an experience exchange and
mutual communication platform for owners and investors of
high-tech, environmental protection, energy resource,
agricultural projects, etc. and push on the healthy, fast
and sustained development of various industrial economies,
"2007's first forum on international capital and
China's industrial development and international
cooperative project negotiations conference" under the
organization of China High-tech Industrialization
Association will be held as a grand conference in the
international investment field and function as a business
platform for extensive exchange and cooperation of
international economies! 

    Forward-Looking Statements 

    Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995: This release contains
forward-looking information. Statements that are not
descriptions of historical facts are forward-looking
statements provided under the "safe harbor"
protection of the Private Securities Litigation Reform Act
of 1995. Examples of forward-looking statements are
statements about anticipated financial or operating
results, financial projections, business prospects, future
product performance and other matters that are not
historical facts. Such statements often include words such
as "believes," "expects,"
"anticipates," "intends,"
"plans," "estimates" or similar
expressions.


    For more information, please contact: 

     Genesis Bioventures, Inc.
     Mr. Douglas C. Lane, CEO
     Tel: [phone]
     Web: http://www.gnsbio.com